The clinical-stage BioPharma company is focused on finding novel treatments for diseases such as diabetes, metabolic syndrome, and cancer. They are in the process of licensing early- and late-stage compounds to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity. Additionally, they have developed INT131, a non-TZD peroxisome proliferator-activated receptor gamma modulator, to treat Relapsing Remitting Multiple Sclerosis by providing neuroprotection and stopping the progression of the disease.